NetraMark Holdings (XCNQ:AIAI) Cash, Cash Equivalents, Marketable Securities : C$0.26 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NetraMark Holdings Cash, Cash Equivalents, Marketable Securities?

NetraMark Holdings's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (C$1.78 Mil) to Dec. 2023 (C$0.82 Mil) but then stayed the same from Dec. 2023 (C$0.82 Mil) to Mar. 2024 (C$0.26 Mil).

NetraMark Holdings's annual cash, cash equivalents, marketable securities declined from Sep. 2021 (C$6.33 Mil) to Sep. 2022 (C$0.02 Mil) but then increased from Sep. 2022 (C$0.02 Mil) to Sep. 2023 (C$1.78 Mil).

NetraMark Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for NetraMark Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NetraMark Holdings Cash, Cash Equivalents, Marketable Securities Chart

NetraMark Holdings Annual Data

Trend

Sep20

Sep21

Sep22

Sep23

Cash, Cash Equivalents, Marketable Securities

1.84

6.33

0.02

1.78

NetraMark Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial										0.20	0.57	1.78	0.82	0.26

NetraMark Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

NetraMark Holdings (XCNQ:AIAI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

NetraMark Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of NetraMark Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

NetraMark Holdings (XCNQ:AIAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » NetraMark Holdings Inc (XCNQ:AIAI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

AINMF:USA

Address

1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1

Website

https://www.nurosene.com

NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.

Executives

Andrew Parks

Director

NetraMark Holdings (XCNQ:AIAI) Headlines

No Headlines